NSB NeuroScientific Biopharmaceuticals Limited
—Mkt Cap: —P/E: —1d ago
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB d…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value13.29M USD
Revenue (TTM)278.27K USD
Gross Profit178.49K USD
Net Income (TTM)-3.24M USD
Revenue/Share0.0010 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000012973
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.79
EV/Revenue47.76
P/S59.04
P/B1.61
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin64.14%
Oper. Margin-3407.53%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-31.69%
ROA-30.91%
Growth
Revenue Growth87.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.92M USD
CapEx (TTM)—
FCF Margin-257.75%
FCF Yield—
Net Debt-3.14M USD
Net Debt/EBITDA1.37
Balance Sheet
Debt/Equity0.01
Current Ratio14.27
Quick Ratio14.15
Book Value/Sh0.04 AUD
Cash/Share0.01 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.4300 AUD
Target Range0.4300 AUD – 0.4300 AUD
# Analysts1
Ownership
Shares Out.389.72M
Float152.64M
Insiders45.21%
Institutions0.00%
Technical
SMA 500.0615 AUD
SMA 2000.0880 AUD
Beta1.23
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)106.80K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—